[Therapeutic efficacy of iodine 131 in autonomous thyroid adenomas--59 cases].
Explore the source record for details and available documents.
Adenoma↗
Biomedical subjects
F Guermazi
Publications and source records attributed to F Guermazi.
[Therapeutic efficiency of iodine 131 in autonomous thyroid adenoma and toxic multinodular goiter. Apropos of 59 cases].
Our study dealt with 81 patients treated by iodine 131 for autonomous goiter. We have followed 59 patients during about a year. The global therapeutic efficiency is of 73% and the risk of hypothyroidism is very weak. The administration of a high activity (greater than 15 mCi) of iodine allows to get a faster recovery, a better therapeutic efficiency and permits to reduce the number of cures (therefore, to reduce the irradiation of the patient), nevertheless, the risk of hypothyroidism is very slight. The advantages of metabolic radiotherapy (low cost, facility of administration, efficiency) make it preferable to surgery, above all with patients that are more than 40 years old, for whom the radiation risk is practically null (hereditary diseases, cancer).
Adenoma↗
[Iodine-131 treatment of cardiothyrotoxicosis (apropos of 21 cases)].
Explore the source record for details and available documents.
Female↗
Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans.
Explore the source record for details and available documents.
3-Iodobenzylguanidine↗
[Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases].
Seventy children (3.7 +/- 3.3 y) with definitely confirmed diagnosis of neuroblastoma had 115 whole body scans carried out 24 h after injection of 3.7 MBq/kg of I-123 mIBG (83 scans) or 0.7 MBq/kg of I-131 mIBG (17 scans) or 0.9 to 4.5 GBq of I-131 mIBG (15 post-therapeutic scans). The scans were interpreted as positive in the presence of any non-physiological uptake area or of any bone uptake of the tracer, even at the level of the metaphyseal complex. For the primary tumour, the sensitivity of mIBG scans was 73%. Ten false negative patients had an overlap of the tumour with the bladder or heart images (4 cases) or with positive metastatic images (6 cases: liver, spine). Three false negative patients had neuroblastomas which did not secrete catecholamines. The specificity of mIBG was 94%. In our opinion, mIBG scans have a complementary role to assess the activity of post-therapeutic remnants. For the detection of hepatic and lymph node metastases, the sensitivity was about 50% and the specificity was 100%. The standard used for the detection of bone marrow metastases was the cytological and histological examination of 10 bone marrow aspirations and one or more biopsies (CHBMS). The sensitivity of mIBG scans was 90% and the specificity 68%. However, reviewing the data from the 16 false positive scans, we found 11 definitely proven bone metastases, 3 biological relapses and 2 cases of delayed abnormal CHBMS supporting the positivity of the mIBG scans, raising the specificity to 100%. Tc-99m diphosphonate bone scans had a sensitivity of 78% and a specificity of 51%. We suggest that positive mIBG scans may save other procedures since our data do not support false positive detection of bone or bone marrow metastases. In contrast, patients with negative mIBG findings should be further explored.
3-Iodobenzylguanidine↗